- The key vendors in the Global Cardiac Biomarkers Market 2014-2018 are Abbott Laboratories, Alere Inc., Ortho Clinical Diagnostics Inc. and Roche Diagnostics.
London, 28 October 2014: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Cardiac Biomarkers Market 2014-2018. The identification of new cardiac biomarkers (H-FABP, GPBB, Urotensin II, and S-100 as potential cardiac biomarkers) and the advances being made in diagnostic technologies are some of the major trends uocoming in this market. The Global Cardiac Biomarkers market is expected to post a CAGR of 12.75 percent during the forecast period of 2013-2018.
The growth of the Global Cardiac Biomarkers market is increased by the increase in CVDs because cardiac diseases are a leading cause of mortality worldwide. The development of new congestive heart failure biomarkers, growing market in POC testing, and approval of stroke biomarkers contribute to the growth of this market.
“Vendors in the Global Cardiac Biomarkers market are focusing on technological advances and are working on product characterization, which may help perform clinical procedures in advanced levels,” says Faisal Ghaus, Vice President of TechNavio Research.
“Advances in diagnostic technologies have enabled the discovery of new products that focus on the identification of a specific therapeutic area or platform that helps meet the unmet medical needs in cardiac biomarkers.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
